Santhera Pharmaceuticals Holding AG (SANN.S)
15 Aug 2018
ZURICH, June 22 The Swiss blue-chip SMI was seen opening 0.2 percent higher at 8473 points on Friday, according to premarket indications by bank Julius Baer .
* UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* SANTHERA SUBMITS NDA IN SOUTH KOREA FOR RAXONE® FOR THE TREATMENT OF LHON
BRIEF-Santhera Successfully Completes First Clinical Trial With Omigapil In Patients With Congenital Muscular Dystrophy
* SUCCESSFUL COMPLETION OF FIRST CLINICAL TRIAL WITH OMIGAPIL IN PATIENTS WITH CONGENITAL MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)
ZURICH, March 20 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 8,841 points on Tuesday, according to premarket indications by bank Julius Baer .
* SANTHERA PHARMACEUTICALS - FY NET REVENUES FROM SALES OF LEAD PRODUCT RAXONE® INCREASED BY 21% TO CHF 22.9 MILLION
ZURICH Santhera Pharmaceuticals said on Monday a study of its medicine Raxone in primary progressive multiple sclerosis showed no difference between the treatment and placebo groups in disease progression, another setback for the Swiss drug company.
BRIEF-Santhera Pharmaceuticals Reports Outcome Of Exploratory Trial With Idebenone In PPMS Conducted At NIH
* REPORTS OUTCOME OF EXPLORATORY TRIAL WITH IDEBENONE IN PPMS CONDUCTED AT NIH
* SANTHERA COMPLETES CAPITAL INCREASE TO SETTLE OBTAINED LICENSE FROM POLYPHOR